Thymosin alpha-1 + TB-500
Not FDA approvedUnapproved peptide blend
Very thin human evidence
- Regulatory standing. Sold as a research chemical, not approved
- Anecdotal. Community reports, no controlled data
- No registered human trials. Nothing registered on ClinicalTrials.gov
- No sources. Nothing cited to verify
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
This is a combination product containing thymosin alpha-1, a 28-amino-acid peptide originally isolated from thymus tissue that is thought to modulate immune cell activity, and TB-500, a synthetic fragment related to thymosin beta-4 that is thought to influence cell migration and tissue repair. The blend is marketed on the idea that the two components act on different pathways, but this rationale has not been formally tested.
What the evidence shows
Thymosin alpha-1 on its own has been studied in humans and is approved in some countries outside the US (as thymalfasin), while TB-500 has mostly animal and lab data. No registered human trials or published studies of this specific combination were identified, so its effects and safety as a blend are unknown.
What is in this blend
A blend is scored on its own, but the evidence for each ingredient lives on its own profile. Mixing compounds adds unknowns that none of the individual studies cover.
Sources
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.